[1]何金龙.射血分数降低心力衰竭患者血清G-17水平检测及其意义[J].医学信息,2022,35(17):49-52.[doi:10.3969/j.issn.1006-1959.2022.17.011]
　HE Jin-long.Detection of Serum G-17 Level in Heart Failure Patients with Reduced Ejection Fraction and its Significance[J].Journal of Medical Information,2022,35(17):49-52.[doi:10.3969/j.issn.1006-1959.2022.17.011]
点击复制

射血分数降低心力衰竭患者血清G-17水平检测及其意义()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年17期
页码:
49-52
栏目:
论著
出版日期:
2022-09-01

文章信息/Info

Title:
Detection of Serum G-17 Level in Heart Failure Patients with Reduced Ejection Fraction and its Significance
文章编号:
1006-1959（2022）17-0049-04
作者:
何金龙
（广西中医药大学附属瑞康医院心血管内科，广西 南宁 530000）
Author(s):
HE Jin-long
(Department of Cardiology,Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine,Nanning 530000,Guangxi,China)
关键词:
胃泌素; 射血分数降低心力衰竭; N-末端B型脑钠肽前体
Keywords:
Gastrin; Heart failure with reduced ejection fraction; N-terminal B-type pro brain natriuretic peptide
分类号:
R541.6
DOI:
10.3969/j.issn.1006-1959.2022.17.011
文献标志码:
A
摘要:
目的 探讨射血分数降低心力衰竭（HFrEF）患者G-17表达水平及其意义。方法 选取2019年1月1日-2021年12月30日广西中医药大学附属瑞康医院心内科住院治疗的患者160例作为研究对象，将符合HFrEF诊断标准的80例患者作为心力衰竭组，另将同期住院匹配的80例非心力衰竭患者作为对照组，比较心力衰竭组和对照组及不同NYHA分级患者NT-proBNP、LVEF、G-17水平，并分析血清G-17水平与NT-proBNP、LVEF的相关性。结果 心力衰竭组NT-proBNP、G-17水平高于对照组、而LVEF低于对照组，差异有统计学意义（P＜0.05）；心力衰竭组NYHAⅢ、Ⅳ级NT-proBNP水平高于NYHAⅡ级、而LVEF低于NYHAⅡ级；NYHAⅢ、Ⅳ级组血清G-17水平均高于NYHAⅡ级组，差异有统计学意义（P＜0.05）；Pearson 相关性分析显示，G-17与NT-proBNP呈正相关（r=0.4708，P＜0.05），与LVEF呈负相关（r=-0.5028，P＜0.05）。结论 HFrEF患者血清G-17表达水平较高，血清G-17水平与NT-proBNP、LVEF密切相关，而G-17表达异常可能参与了心力衰竭发生发展的进程，有可能成为HFrEF患者重要的风险预测因子，具有潜在的临床应用价值。
Abstract:
Objective To investigate the expression level and significance of G-17 in patients with heart failure with reduced ejection fraction.Methods A total of 160 patients hospitalized in the Department of Cardiology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine from January 1, 2019 to December 30, 2021 were selected as the study subjects. Eighty patients who met the diagnostic criteria for HFrEF were included in the heart failure group, and 80 non-heart failure patients who were hospitalized during the same period were included in the control group. The levels of NT-proBNP, LVEF, and G-17 were compared between the heart failure group and the control group, as well as patients with different NYHA grades. The correlation between serum G-17 levels and NT-proBNP and LVEF was analyzed.Results The levels of NT-proBNP and G-17 in the heart failure group were higher than those in the control group, while the LVEF was lower than that in the control group, the difference was statistically significant (P<0.05). The NT-proBNP level of NYHAⅢ and Ⅳ in heart failure group was higher than that of NYHAⅡ, while LVEF was lower than that of NYHAⅡ, the serum G-17 level in NYHAⅢ and Ⅳ groups was higher than that in NYHAⅡ group, and the difference was statistically significant (P<0.05). Pearson correlation analysis showed that G-17 was positively correlated with NT-proBNP (r=0.4708, P<0.05) and negatively correlated with LVEF (r=-0.5028, P<0.05).Conclusion The expression level of serum G-17 in patients with HFrEF is higher, and the level of serum G-17 is closely related to NT-proBNP and LVEF. The abnormal expression of G-17 may be involved in the development of heart failure, which may be an important risk predictor for HFrEF patients and has potential clinical application value.

参考文献/References:

[1]Fu J,Tang Y,Zhang Z,et al.Gastrin exerts a protective effect against myocardial infarction via promoting angiogenesis[J].Mol Med,2021,27(1):90.[2]Duan S,Rico K,Merchant JL.Gastrin: From Physiology to Gastrointestinal Malignancies[J].Function(Oxf),2021,3(1):zqab062. [3]庞玉生,何伟生,韦丹,等.心力衰竭患儿血清胃泌素的变化及其临床意义[J].华夏医学,2003,16(6):773-774.[4]刘晓玲,张爱军,李洋,等.自拟养胃护心汤对慢性心力衰竭患者症状缓解期食欲减退的疗效观察[J].世界中医药,2017,12(8):1852-1854.[5]Ueland T,Gullestad L,Kou L,et al.Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study[J].ESC Heart Fail,2018,5(6):1052-1059. [6]Heidenreich PA,Bozkurt B,Aguilar D,et al.2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J].Circulation,2022,145(18):e895-e1032[7]McDonagh TA,Metra M,Adamo M,et al.2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J].Eur Heart J,2021,42(36):3599-3726. [8]Yeoh SE,Dewan P,Serenelli M,et al.Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES[J].Eur J Heart Fail,2022,24(3):529-538[9]Abraityte A,Aukrust P,Kou L,et al.T cell and monocyte/macrophage activation markers associate with adverse outcome,but give limited prognostic value in anemic patients with heart failure: results from RED-HF[J].Clin Res Cardiol,2019,108(2):133-141.[10]Pontremoli R,Borghi C,Perrone Filardi P.Renal protection in chronic heart failure: focus on sacubitril/valsartan[J].Eur Heart J Cardiovasc Pharmacother,2021,7(5):445-452.[11]Vinther M,Risum N,Svendsen JH,et al.A Randomized Trial of His Pacing Versus Biventricular Pacing in Symptomatic HF Patients With Left Bundle Branch Block (His-Alternative)[J].JACC Clin Electrophysiol,2021,7(11):1422-1432.[12]Steyaert W,Varney MJ,Benovic JL,et al.Hypergastrinemia,a clue leading to the identification of an atypical form of diabetes mellitus type 2[J].Clin Chim Acta,2022,532:79-83.[13]Wang Z,Mo TM,Tian L,et al.Gastrin-17 Combined with CEA,CA12-5 and CA19-9 Improves the Sensitivity for the Diagnosis of Gastric Cancer[J].Int J Gen Med,2021,14:8087-8095.[14]Kruszelnicka O,Kuzma M,Pena IZ,et al.No Association of Proton Pump Inhibitor Use with Fasting or Postload Glycaemia in Patients with Cardiovascular Disease: A Cross-Sectional Retrospective Study[J].Int J Med Sci,2017,14(10):1015-1021.[15]Goetze JP,Rehfeld JF,Alehagen U.Cholecystokinin in plasma predicts cardiovascular mortality in elderly females[J].Int J Cardiol,2016,209:37-41.[16]Andersen U?覫,Terzic D,Wewer Albrechtsen NJ,et al.Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma[J].Endocr Connect,2020,9(5):438-444. [17]Burchill LJ,Lee MGY,Nguyen VP,et al.Heart Failure in Adult Congenital Heart Disease[J].Cardiol Clin,2020,38(3):457-469.[18]Yang X,Yue R,Zhang J,et al.Gastrin Protects Against Myocardial Ischemia/Reperfusion Injury via Activation of RISK (Reperfusion Injury Salvage Kinase) and SAFE (Survivor Activating Factor Enhancement) Pathways[J].J Am Heart Assoc,2018,7(14):e005171.[19]Yeoh SE,Dewan P,Serenelli M,et al.Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES[J].Eur J Heart Fail,2022,24(3):529-538.[20]Wang R,Zhang Z,Xu Z,et al.Gastrin mediates cardioprotection through angiogenesis after myocardial infarction by activating the HIF-1α/VEGF signalling pathway[J].Sci Rep,2021,11(1):15836. [21]Welsh P,Kou L,Yu C,et al.Prognostic importance of emerging cardiac,inflammatory,and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study[J].Eur J Heart Fail,2018,20(2):268-277. [22]Gohar A,Chong JPC,Liew OW,et al.The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction[J].Eur J Heart Fail,2017,19(12):1638-1647. [23]Santhanakrishnan R,Chong JP,Ng TP,et al.Growth differentiation factor 15,ST2,high-sensitivity troponin T,and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction[J].Eur J Heart Fail,2012,14(12):1338-1347. [24]Chen F,Tian G,Bai X,et al.The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction[J].Ann Palliat Med,2021,10(8):8684-8691.[25]Santaguida PL,Don-Wauchope AC,Oremus M,et al.BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review[J].Heart Fail Rev,2014,19(4):453-470. [26]Salah K,Stienen S,Pinto YM,et al.Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction[J].Heart,2019,105(15):1182-1189.

相似文献/References:

[1]吴忠军,林 涛,胡 彬.兰索拉唑、奥曲肽、凝血酶三联治疗重症上消化道出血的临床疗效及并发症观察[J].医学信息,2021,34(24):64.[doi:10.3969/j.issn.1006-1959.2021.24.013]
　WU Zhong-jun,LIN Tao,HU Bin.Clinical Effects and Complications of Lansoprazole, Octreotide and Thrombin in the Treatment of Severe Upper Gastrointestinal Hemorrhage[J].Journal of Medical Information,2021,34(17):64.[doi:10.3969/j.issn.1006-1959.2021.24.013]
[2]黄 飞.不同用药方案治疗幽门螺杆菌感染胃溃疡的效果比较[J].医学信息,2020,33(16):156.[doi:10.3969/j.issn.1006-1959.2020.16.050]
　HUANG Fei.Comparison of the Effects of Different Medication Regimens in the Treatment of Gastric Ulcer Infected by Helicobacter Pylori[J].Journal of Medical Information,2020,33(17):156.[doi:10.3969/j.issn.1006-1959.2020.16.050]
[3]李 杰.奥美拉唑联合铝碳酸镁对反流性食管炎患者临床症状及血清胃泌素水平的影响[J].医学信息,2022,35(06):153.[doi:10.3969/j.issn.1006-1959.2022.06.039]
　LI Jie.Effect of Omeprazole Combined with Aluminum Magnesium Carbonate on Clinical Symptoms and Serum Gastrin Level in Patients with Reflux Esophagitis[J].Journal of Medical Information,2022,35(17):153.[doi:10.3969/j.issn.1006-1959.2022.06.039]

更新日期/Last Update: 1900-01-01